COMPLETED

Enhancing Prospective Thinking in Early Recovery (PARK)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to demonstrate the commercial potential for a novel virtual reality (VR) intervention in preparation for Phase II development. This clinical trial will test the VR intervention for efficacy in reducing opioid use, increasing abstinence, and other self-reported and behavioral focus on future outcomes in individuals in early recovery from opioid use disorder. * Will the VR group, compared to the control group, have a lower number of opioid use days? * Will the VR group, compared to the control group, have longer periods of abstinence at the 30-day follow-up? * Will the VR group, compared to the control group, have significantly increased opioid abstinence rates? * Will the VR group, compared to baseline and the control group, show increased future self-identification post-VR intervention? * Will the VR group, compared to baseline and the control group, show increased future orientation post-VR intervention? * Will the VR group, compared to baseline and the control group, show an increased preference for delayed rewards in a laboratory delay discounting task post-VR intervention? * Will the VR group, compared to baseline and the control group, exceed in behavioral effects (i.e., future self-identification, future orientation, and increased preference for delayed rewards) at the 30-day follow-up? Researchers will compare the VR test group and the control group to see if there are differences in the results for the questions outlined above.

Official Title

Enhancing Prospective Thinking in Early Recovery

Quick Facts

Study Start:2023-04-04
Study Completion:2025-09-14
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05908097

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Abstinence between ≥14 days and ≤ 1 year
  2. * 18-60 years old
  3. * Verbal endorsement of commitment to recovery
  4. * Outpatient
  5. * Psychotropic drugs for SUD-comorbidity
  6. * Mu-Opioid drugs
  7. * Drug/alcohol abstinence ≥ 24 hours at the time of the study day visit
  8. * English comprehension
  1. * Unstable medical disorders
  2. * Outside the age range of 18-60
  3. * Habitual drug use
  4. * Smell/taste disorders
  5. * Unstable psychiatric conditions
  6. * Extravagant/elaborate face tattoos

Contacts and Locations

Principal Investigator

Brandon G Oberlin, PhD
PRINCIPAL_INVESTIGATOR
Indiana University

Study Locations (Sites)

Indiana University School of Medicine - Goodman Hall
Indianapolis, Indiana, 46202
United States
IUSM - Goodman Hall
Indianapolis, Indiana, 46202
United States
Serenity Lane Alcohol & Drug Treatment
Coburg, Oregon, 97402
United States

Collaborators and Investigators

Sponsor: Indiana University

  • Brandon G Oberlin, PhD, PRINCIPAL_INVESTIGATOR, Indiana University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-04
Study Completion Date2025-09-14

Study Record Updates

Study Start Date2023-04-04
Study Completion Date2025-09-14

Terms related to this study

Additional Relevant MeSH Terms

  • Opioid Use
  • Opioid Use Disorder
  • Substance Use Disorders